Treatment of castration‐resistant prostate cancer and bone metastases with radium‐223 dichloride

This article, which draws on the experiences of health care workers during the ALSYMPCA (ALpharadin in SYMtomatic Prostate CAncer) study, reviews the clinical development of Ra‐223, highlighting the key issues for the uro‐oncology nurse who has a pivotal role within the multi‐disciplinary team (MDT) to ensure safe and effective treatment to the patient. The role of the uro‐oncology nurse is multifaceted, including patient pre‐assessment and post‐treatment monitoring and coordination of the MDT. In addition, their role in communicating with and educating those involved with Ra‐223 on what to expect from the agent can alleviate fears associated with its use.
Source: International Journal of Urological Nursing - Category: Urology & Nephrology Authors: Tags: Review Paper Source Type: research